CRNX
Crinetics Pharmaceuticals Inc
NASDAQ: CRNX · HEALTHCARE · BIOTECHNOLOGY
$83.88
+0.02% today
Updated 2026-07-29
Market cap
$8.88B
P/E ratio
—
P/S ratio
491.21x
EPS (TTM)
$-5.14
Dividend yield
—
52W range
$26 – $84
Volume
4.2M
Crinetics Pharmaceuticals Inc (CRNX) Insider transactions
Net insider activity
Net buying (190,365 shares)
Buy transactions
53
Sell transactions
47
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | VIVALDI, COELHO ROGERIO | Director | Sale | 3,000 | $40.00 | $120000.00 |
| 2026-06-18 | WIERENGA, WENDELL | Director | Buy | 9,730 | — | — |
| 2026-06-18 | WIERENGA, WENDELL | Director | Buy | 5,925 | — | — |
| 2026-06-18 | VIVALDI, COELHO ROGERIO | Director | Buy | 9,730 | — | — |
| 2026-06-18 | VIVALDI, COELHO ROGERIO | Director | Buy | 5,925 | — | — |
| 2026-06-18 | OKEY, STEPHANIE | Director | Buy | 9,730 | — | — |
| 2026-06-18 | OKEY, STEPHANIE | Director | Buy | 5,925 | — | — |
| 2026-06-18 | NICHOLS, WESTON | Director | Buy | 9,730 | — | — |
| 2026-06-18 | NICHOLS, WESTON | Director | Buy | 5,925 | — | — |
| 2026-06-18 | FUST, MATTHEW K | Director | Buy | 9,730 | — | — |
| 2026-06-18 | FUST, MATTHEW K | Director | Buy | 5,925 | — | — |
| 2026-06-18 | DEARDORF, CAREN | Director | Buy | 9,730 | — | — |
| 2026-06-18 | DEARDORF, CAREN | Director | Buy | 5,925 | — | — |
| 2026-06-18 | BEDROSIAN, CAMILLE L | Director | Buy | 9,730 | — | — |
| 2026-06-18 | BEDROSIAN, CAMILLE L | Director | Buy | 5,925 | — | — |
| 2026-06-17 | OKEY, STEPHANIE | Director | Sale | 6,292 | $35.62 | $224121.04 |
| 2026-06-17 | OKEY, STEPHANIE | Director | Sale | 608 | $36.22 | $22021.76 |
| 2026-05-29 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 222,200 | — | — |
| 2026-05-29 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 111,100 | — | — |
| 2026-05-29 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 80,000 | — | — |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Sale | 49,474 | — | — |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Sale | 19,336 | — | — |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Sale | 9,624 | — | — |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Sale | 85,163 | $40.10 | $3.42M |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Buy | 49,474 | $23.98 | $1.19M |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Buy | 19,336 | $19.64 | $379759.04 |
| 2026-04-08 | KNIGHT, JEFF E. | Chief Dev. & Operating Officer | Buy | 9,624 | $20.02 | $192672.48 |
| 2026-03-16 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 13,196 | $37.11 | $489703.56 |
| 2026-03-16 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 8,785 | $37.77 | $331809.45 |
| 2026-03-16 | KNIGHT, JEFF E. | Chief Operating Officer | Sale | 5,950 | $37.11 | $220804.50 |
| 2026-03-16 | KNIGHT, JEFF E. | Chief Operating Officer | Sale | 3,961 | $37.77 | $149606.97 |
| 2026-03-16 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 6,371 | $37.11 | $236427.81 |
| 2026-03-16 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 4,241 | $37.77 | $160182.57 |
| 2026-03-12 | VIVALDI, COELHO ROGERIO | Director | Sale | 4,477 | $36.08 | $161530.16 |
| 2026-03-12 | VIVALDI, COELHO ROGERIO | Director | Sale | 523 | $36.77 | $19230.71 |
| 2026-03-03 | SCHILKE, TOBIN | Chief Financial Officer | Sale | 6,713 | $39.67 | $266304.71 |
| 2026-03-03 | OKEY, STEPHANIE | Director | Sale | 3,000 | $39.67 | $119010.00 |
| 2026-02-23 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 228,000 | — | — |
| 2026-02-23 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 62,000 | — | — |
| 2026-02-23 | SCHILKE, TOBIN | Chief Financial Officer | Buy | 50,000 | — | — |
| 2026-02-23 | SCHILKE, TOBIN | Chief Financial Officer | Buy | 32,000 | — | — |
| 2026-02-23 | KNIGHT, JEFF E. | Chief Operating Officer | Buy | 55,000 | — | — |
| 2026-02-23 | KNIGHT, JEFF E. | Chief Operating Officer | Buy | 34,000 | — | — |
| 2026-02-23 | KALOFONOS, ISABEL | Chief Commercial Officer | Buy | 55,000 | — | — |
| 2026-02-23 | KALOFONOS, ISABEL | Chief Commercial Officer | Buy | 34,000 | — | — |
| 2026-02-23 | BETZ, STEPHEN F. | Chief Scientific Officer | Buy | 47,000 | — | — |
| 2026-02-23 | BETZ, STEPHEN F. | Chief Scientific Officer | Buy | 30,000 | — | — |
| 2026-01-05 | KALOFONOS, ISABEL | Chief Commercial Officer | Sale | 2,500 | — | — |
| 2026-01-05 | KALOFONOS, ISABEL | Chief Commercial Officer | Sale | 2,500 | $55.00 | $137500.00 |
| 2025-12-26 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 18,000 | — | — |
| 2025-12-26 | BETZ, STEPHEN F. | Chief Scientific Officer | Buy | 18,000 | $1.91 | $34380.00 |
| 2025-12-18 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 28,400 | — | — |
| 2025-12-18 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 16,342 | — | — |
| 2025-12-18 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 28,400 | $15.29 | $434236.00 |
| 2025-12-18 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 16,342 | $9.28 | $151653.76 |
| 2025-12-01 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 5,000 | — | — |
| 2025-12-01 | PIZZUTI, DANA | Chief Med and Dev Officer | Buy | 5,000 | $16.89 | $84450.00 |
| 2025-11-03 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 5,000 | — | — |
| 2025-11-03 | PIZZUTI, DANA | Chief Med and Dev Officer | Buy | 5,000 | $16.89 | $84450.00 |
| 2025-11-03 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 4,900 | $42.65 | $208985.00 |
| 2025-11-03 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 100 | $43.27 | $4327.00 |
| 2025-10-01 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 5,000 | — | — |
| 2025-10-01 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 5,000 | $41.81 | $209050.00 |
| 2025-09-26 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 4,000 | $45.00 | $180000.00 |
| 2025-09-26 | FUST, MATTHEW K | Director | Sale | 10,000 | — | — |
| 2025-09-26 | FUST, MATTHEW K | Director | Sale | 16,000 | $44.75 | $716000.00 |
| 2025-09-26 | FUST, MATTHEW K | Director | Buy | 10,000 | $1.91 | $19100.00 |
| 2025-09-02 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 5,000 | — | — |
| 2025-09-02 | PIZZUTI, DANA | Chief Med and Dev Officer | Buy | 5,000 | $16.89 | $84450.00 |
| 2025-08-22 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 30,000 | — | — |
| 2025-08-22 | PIZZUTI, DANA | Chief Med and Dev Officer | Buy | 30,000 | $16.89 | $506700.00 |
| 2025-08-20 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 6,492 | $29.18 | $189436.56 |
| 2025-06-12 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 71,525 | — | — |
| 2025-06-12 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 16,645 | — | — |
| 2025-06-12 | BETZ, STEPHEN F. | Chief Scientific Officer | Sale | 97,483 | $32.23 | $3.14M |
| 2025-06-12 | BETZ, STEPHEN F. | Chief Scientific Officer | Buy | 71,525 | $1.91 | $136612.75 |
| 2025-06-12 | BETZ, STEPHEN F. | Chief Scientific Officer | Buy | 16,645 | $9.28 | $154465.60 |
| 2025-06-11 | WIERENGA, WENDALL | Director | Buy | 10,350 | — | — |
| 2025-06-11 | WIERENGA, WENDALL | Director | Buy | 6,900 | — | — |
| 2025-06-11 | VIVALDI, COELHO ROGERIO | Director | Buy | 10,350 | — | — |
| 2025-06-11 | VIVALDI, COELHO ROGERIO | Director | Buy | 6,900 | — | — |
| 2025-06-11 | OKEY, STEPHANIE | Director | Buy | 10,350 | — | — |
| 2025-06-11 | OKEY, STEPHANIE | Director | Buy | 6,900 | — | — |
| 2025-06-11 | NICHOLS, WESTON | Director | Buy | 10,350 | — | — |
| 2025-06-11 | NICHOLS, WESTON | Director | Buy | 6,900 | — | — |
| 2025-06-11 | FUST, MATTHEW K | Director | Buy | 10,350 | — | — |
| 2025-06-11 | FUST, MATTHEW K | Director | Buy | 6,900 | — | — |
| 2025-06-11 | DEARDORF, CAREN | Director | Buy | 10,350 | — | — |
| 2025-06-11 | DEARDORF, CAREN | Director | Buy | 6,900 | — | — |
| 2025-06-11 | BEDROSIAN, CAMILLE L | Director | Buy | 10,350 | — | — |
| 2025-06-11 | BEDROSIAN, CAMILLE L | Director | Buy | 6,900 | — | — |
| 2025-05-14 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 90,400 | — | — |
| 2025-04-02 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 81,270 | — | — |
| 2025-04-02 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Buy | 81,270 | $1.91 | $155225.70 |
| 2025-03-19 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 16,463 | $34.17 | $562540.71 |
| 2025-03-19 | STRUTHERS, RICHARD SCOTT | Director, President & CEO | Sale | 875 | $34.83 | $30476.25 |
| 2025-03-19 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 2,388 | $34.17 | $81597.96 |
| 2025-03-19 | PIZZUTI, DANA | Chief Med and Dev Officer | Sale | 127 | $34.83 | $4423.41 |
| 2025-03-19 | KNIGHT, JEFF E. | Chief Operating Officer | Sale | 6,801 | $34.17 | $232390.17 |
| 2025-03-19 | KNIGHT, JEFF E. | Chief Operating Officer | Sale | 361 | $34.83 | $12573.63 |
Frequently asked questions
Are CRNX insiders buying or selling?
Over the transactions on record, CRNX insiders have been net buyers, with about $11.65M in stock sold across 47 sales, against 14 open-market purchases.
Does insider selling at CRNX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which CRNX insiders are selling the most?
Recent selling is concentrated in a few names. KNIGHT, JEFF E. accounts for the largest share on record, with about $4.03M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.